Market Intelligence, Clinical Progress, and High-Purity Reagents for Synthetic Lethality and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DHX9 (RNA Helicase A) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DHX9 Full-Length / Helicase Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native folding). |
View DHX9 Products |
| Gene Delivery | DHX9 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in synthetic lethality studies. |
View DHX9 Products |
| Benchmark Ab | Anti-DHX9 (Research Grade) Recombinant monoclonal for Western/IP validation. |
View DHX9 Products |
| Validator | DHX9 siRNA Set For specific knockdown validation in RNAi rescue experiments. |
View DHX9 Products |
| Related Target A | BRCA1 Synthetic lethality partner in DNA repair-deficient cancers. |
View BRCA1 Products |
| Related Target B | MYC Co-dependency target in MYC-driven oncogenesis. |
View MYC Products |
| Related Target C | DDX3X Critical paralog for selectivity counter-screening assays. |
View DDX3X Products |
| Related Target D | DHX36 DEAH-box paralog and G-quadruplex resolvase; essential for helicase selectivity counter-screening. |
View DHX36 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Activity Inhibition | Purified DHX9 helicase domain (>95% purity by SDS-PAGE) with intact ATP-binding cassette; low endotoxin (<1EU/ug) ensures no interference with phosphate detection assays. |
| Paralog Selectivity (vs DDX3X/DHX15/DHX36) | Helicase panel available: Human DHX9, DDX3X, DHX15, DHX36 with distinct purification tags for multiplex SPR/binding assays; sequence verified by mass spec. |
| Resistance Mutation Screening | Mutant DHX9 proteins (predicted ATP-pocket variants) available upon request; Sequence-verified ORF clones for rapid custom expression. |
| Synthetic Lethality Validation | Lentiviral ORF particles (Endotoxin <100 EU/mL) for stable overexpression in MYC-amplified or BRCA-deficient cell lines; ideal for CRISPR rescue experiments. |
| Target Engagement & Specificity | Validated siRNA included for loss-of-function checks; mutant variants available for mechanistic deconvolution. |
Live DHX9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Resistance Research
- Latest Helicase Inhibitor Research
- Synthetic Lethality Publications
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for DHX9 (also known as RNA Helicase A or DDX9) therapeutics is accelerating as synthetic lethality screens identify it as a critical dependency in MYC-driven malignancies and ARID1A-deficient tumors. Currently positioned in preclinical and discovery phases, DHX9 has emerged as a high-value target for oncology drug development, particularly for cancers resistant to direct MYC inhibition. As first-generation helicase inhibitors enter IND-enabling studies, the R&D focus is shifting toward overcoming selectivity challenges against closely related DEAD/DEAH-box helicases (e.g., DDX3X, DHX15) and addressing potential resistance mutations in the ATP-binding domain. The next wave of development emphasizes brain-penetrant compounds for glioblastoma applications and PROTAC-based approaches to disrupt scaffolding functions beyond catalytic inhibition. Combination strategies with PARP inhibitors, CDK4/6 inhibitors, or immune checkpoint inhibitors are under active exploration for improved therapeutic index.
Competitive Modality & Indication Snapshot
| Modality | Development Stage | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive) | Preclinical | Solid Tumors (MYC-amp, MSI-High) | ATPase Activity Assay (Need high-purity active enzyme) |
| PROTAC Degraders | Discovery | Triple-Negative Breast Cancer, Refractory Cancers | Ternary Complex Formation (Need full-length protein) |
| RNAi / ASO | Preclinical | MYC-driven Malignancies | Knockdown Validation (Need specific siRNA/Lentivirus) |
| Immunotherapy Combination | Discovery | Tumors with interferon pathway dysregulation | Cell line construction (Need lentivirus for stable expression) |
Key Functional Domains and Genetic Alterations
DHX9 (UniProt Q08211) contains two double-stranded RNA-binding motifs (DRBM 1 and DRBM 2) and a helicase ATP-binding domain that together mediate its RNA unwinding and ATP hydrolysis activities. Clinically relevant mutations associated with MRD75 (mental retardation, autosomal dominant 75) have been identified, including variants of uncertain significance (VAR_090134), likely pathogenic mutations (VAR_090135), and a variant with decreased ATP hydrolysis activity (VAR_090136). These mutations underscore the essential role of DHX9 in neurodevelopment and highlight the need for mutation-selective assay tools.